Waldenstrom Macroglobulinemia

+ -Text Size

Other Resources and References TOPICS

References for Waldenstrom macroglobulinemia

Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.

Dimopoulos MA, Hamilos G, Zervas K, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom’s macroglobulinemia. Annals of Oncology. 2003;14:1299–1305.

Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol. 2009;27:120–126.

Ghobrial IM. Are you sure this is Waldenstrom macroglobulinemia? Hematology Am Soc Hematol Educ Program. 2012;2012:586–594.

Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinemia. Lancet Oncol. 2003;4:679–685.

Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28:1408–1414.

Groves FD, Travis LB, Devesa SS, et al. Waldenstrom’s macroglobulinemia: Incidence patterns in the United States, 1988-1994. Cancer. 1998; 82:1078–1081.

Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstrom’s macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2004; 257–282.

Giordano TP, Henderson L, Landgren O, et al Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010–2017.

Moreau AS, Jia X, Patterson CJ, et al. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008;142:775–785.

Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–4170.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Waldenstrom’s macroglobulinemia/Lymphoplasmacytic lymphoma. V.2.2013. Accessed at www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf on March 5, 2013.

Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30110–30115.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:2323–2351.

Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenström macroglobulinemia: A Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma. 2012;53:1625–1626.

Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2009;114:2375–2385.

Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom’s macroglobulinemia. Ann Oncol. 2006;17:488–494.

Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2009;15:355–360.

Treon SP, Hatjiharissi E, Leleu X, et al. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop H, eds. Hematology, Basic Principles and Practice. 5th edition. Philadelphia, Pa. Elsevier, 2009: 1413–1422.

Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367:826–833.

Young JL, Ward KC, Ries LAG. Cancers of Rare Sites. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.

Last Medical Review: 06/19/2013
Last Revised: 06/19/2013